Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
BioArctic AB (publ)
BIOA-BBioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden. Address: Warfvinges vag 35, Stockholm, Sweden, 112 51
Analytics
Precio Objetivo de WallStreet
3 229.3 SEKRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave BIOA-B
Análisis de dividendos BIOA-B
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
155 %Tendencia del payout BIOA-B
Valoración de la acción BIOA-B
Finanzas BIOA-B
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |